While the maintenance of an Outperform rating suggests continued confidence in ACADIA Pharmaceuticals' long-term prospects, the reduction in the price target could indicate near-term challenges or adjustments in valuation expectations. This mixed signal might lead to short-term market uncertainty for ACAD, potentially limiting its stock price movement.